Myfortic (Mycophenolic Acid)

Mycophenolic acid blocks inosine monophosphate dehydrogenase, an enzyme essential for making guanosine nucleotides. Lymphocytes depend on this pathway for proliferation, so the drug selectively limits T‑ and B‑cell growth, dampening the immune reaction that could lead to transplant rejection.

The dosage of Myfortic is individualized by the prescribing clinician based on the type of transplant, patient weight, renal function and other medications. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for Myfortic in pregnancy and lactation are limited. The drug may pose risks to the fetus and infant, so it should only be used if the potential benefit justifies the potential harm. Women should discuss family planning and breastfeeding with their physician before starting therapy.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that specifically inhibits lymphocyte proliferation, whereas calcineurin inhibitors such as cyclosporine or tacrolimus act on T‑cell activation pathways. Myfortic is often combined with a calcineurin inhibitor to achieve synergistic immunosuppression while allowing lower doses of each drug.

Store Myfortic at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, direct sunlight and excessive heat to maintain stability and potency throughout the shelf life.

Myfortic is taken orally, usually as delayed‑release tablets. The tablets should be swallowed whole with water and not crushed, chewed or split, to ensure proper release and absorption of the active ingredient.

Serious risks include severe infections, leukopenia or other bone‑marrow suppression, liver dysfunction, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for blood‑count changes, liver enzymes and signs of infection, and any concerning symptoms reported promptly.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should be used with caution in individuals with severe renal impairment, active uncontrolled infections, or those receiving live vaccines. A healthcare professional must evaluate suitability before initiating therapy.